Hande Kizilocak1, Elizabeth Marquez-Casas1, Jemily Malvar2, Roxana Carmona1, Guy Young1,2,3. 1. Children's Hospital Los Angeles, Hemostasis and Thrombosis Center, Los Angeles, California, USA. 2. Children's Hospital Los Angeles, Cancer and Blood Disease Institute, Los Angeles, California, USA. 3. Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Abstract
INTRODUCTION: Emicizumab is a recombinant, humanized bispecific monoclonal antibody that mimics the function of factor VIII (FVIII) which results in a significant reduction in the annualized bleeding rate in patients with haemophilia A (HA), however, the degree with which emicizumab corrects the coagulation defect remains unclear. The objective of this study was to predict the approximate FVIII level in severe haemophilia A patients with inhibitors on emicizumab using global haemostasis assays. MATERIALS AND METHODS: Patients with moderate and mild HA in the non-bleeding state and healthy controls had FVIII levels and thrombin generation assessed. Linear regression was utilized to model the FVIII levels as a function of the thrombin generation assay parameters and to make a calibration curve of FVIII levels versus peak thrombin and endogenous thrombin potential. Patients with severe haemophilia A with inhibitors on emicizumab had thrombin generation performed in the same manner and their peak thrombin and endogenous thrombin potential results were placed on the calibration curve to calculate their FVIII Equivalency of Emicizumab by Thrombin Generation (F8EmT). RESULTS: All patients with severe HA with inhibitors on emicizumab had F8EmT >10%, suggesting they had been converted to a mild haemophilia phenotype. The patient's weight was inversely correlated to their F8EmT. CONCLUSION: The results from this study suggest that the F8EmT in patients with severe HA on emicizumab falls within the range of mild haemophilia which is consistent with the data noted in the emicizumab clinical trials and in vivo studies in animals.
INTRODUCTION:Emicizumab is a recombinant, humanized bispecific monoclonal antibody that mimics the function of factor VIII (FVIII) which results in a significant reduction in the annualized bleeding rate in patients with haemophilia A (HA), however, the degree with which emicizumab corrects the coagulation defect remains unclear. The objective of this study was to predict the approximate FVIII level in severe haemophilia Apatients with inhibitors on emicizumab using global haemostasis assays. MATERIALS AND METHODS:Patients with moderate and mild HA in the non-bleeding state and healthy controls had FVIII levels and thrombin generation assessed. Linear regression was utilized to model the FVIII levels as a function of the thrombin generation assay parameters and to make a calibration curve of FVIII levels versus peak thrombin and endogenous thrombin potential. Patients with severe haemophilia A with inhibitors on emicizumab had thrombin generation performed in the same manner and their peak thrombin and endogenous thrombin potential results were placed on the calibration curve to calculate their FVIII Equivalency of Emicizumab by Thrombin Generation (F8EmT). RESULTS: All patients with severe HA with inhibitors on emicizumab had F8EmT >10%, suggesting they had been converted to a mild haemophilia phenotype. The patient's weight was inversely correlated to their F8EmT. CONCLUSION: The results from this study suggest that the F8EmT in patients with severe HA on emicizumab falls within the range of mild haemophilia which is consistent with the data noted in the emicizumab clinical trials and in vivo studies in animals.
Authors: Angelika Batorova; Ana Boban; Melen Brinza; Toshiko Lissitchkov; Laszlo Nemes; Irena Zupan Preložnik; Petr Smejkal; Nadezhda Zozulya; Jerzy Windyga Journal: J Med Life Date: 2022-04
Authors: Fabienne R Kloosterman; Anne-Fleur Zwagemaker; Catherine N Bagot; Erik A M Beckers; Giancarlo Castaman; Marjon H Cnossen; Peter W Collins; Charles Hay; Michel Hof; Britta Laros-van Gorkom; Frank W G Leebeek; Christoph Male; Karina Meijer; Ingrid Pabinger; Susan Shapiro; Michiel Coppens; Karin Fijnvandraat; Samantha C Gouw Journal: Blood Adv Date: 2022-07-26
Authors: Anne-Fleur Zwagemaker; Fabienne R Kloosterman; Robert Hemke; Samantha C Gouw; Michiel Coppens; Lorenzo G R Romano; Marieke J H A Kruip; Marjon H Cnossen; Frank W G Leebeek; Barbara A Hutten; Mario Maas; Karin Fijnvandraat Journal: J Thromb Haemost Date: 2022-03-07 Impact factor: 16.036